本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Tscan Therapeutics, Inc.

0.7795
+0.00330.43%
盤後0.77950.00000.00%19:30 EDT
成交量:13.62萬
成交額:10.63萬
市值:5,283.39萬
市盈率:-0.87
高:0.7900
開:0.7900
低:0.7718
收:0.7762
52周最高:2.57
52周最低:0.7160
股本:6,777.93萬
流通股本:5,781.86萬
量比:0.40
換手率:0.24%
股息:- -
股息率:- -
每股收益(TTM):-0.9000
每股收益(LYR):-2.2805
淨資產收益率:-95.80%
總資產收益率:-31.53%
市淨率:0.77
市盈率(LYR):-0.34

資料載入中...

公司資料

公司名字:
Tscan Therapeutics, Inc.
交易所:
NASDAQ
成立時間:
2018
員工人數:
138
公司地址:
830 Winter Street,Waltham,Massachusetts,United States
郵編:
02451
電話:
傳真:
- -
簡介:
TScan Therapeutics, Inc.於2018年4月17日在特拉華州註冊成立。該公司是一家臨床前階段的生物製藥公司,專註於開發強大的T細胞受體工程T細胞或TCR-T療法,用於治療癌症患者。

董事

名稱
職位
Gavin MacBeath
Chief Executive Officer and Director
Barbara Klencke
Independent Director
Gabriela Gruia
Independent Director
Garry Nicholson
Independent Director
Katina Dorton
Independent Director
R. Keith Woods
Independent Director
Stephen Biggar
Chair of the Board and Independent Director

股東

名稱
職位
Gavin MacBeath
Chief Executive Officer and Director
Jason A. Amello
Chief Financial Officer and Treasurer
Chrystal Louis
Chief Medical Officer
Zoran Zdraveski
Chief Legal and Strategy Officer and Secretary